Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
about
Comparative analysis and modeling of the severity of steatohepatitis in DDC-treated mouse strainsResistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?New perspectives in glioblastoma antiangiogenic therapyProfile of nintedanib in the treatment of solid tumors: the evidence to dateACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferationCardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational studyTargeting vascular endothelial growth factor receptor 2 and protein kinase D1 related pathways by a multiple kinase inhibitor in angiogenesis and inflammation related processes in vitroALK-rearrangements and testing methods in non-small cell lung cancer: a reviewPhysiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryAurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents.Identification of a Mitochondrial DNA Polymerase Affecting Cardiotoxicity of Sunitinib Using a Genome-Wide Screening on S. pombe Deletion Library.Targeting angiogenesis in metastatic breast cancerFocal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular CarcinomaPharmacological Modulation of the N-End Rule Pathway and Its Therapeutic Implications.Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily.Advanced medullary thyroid cancer: pathophysiology and managementThe protein kinase promiscuities in the cancer-preventive mechanisms of NSAIDs.Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy.Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Republished: Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.Innovative computer-aided methods for the discovery of new kinase ligands.Exploiting receptor tyrosine kinase co-activation for cancer therapy.Novel Approaches to Apoptosis-Inducing Therapies.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Progress in tumor-associated macrophage (TAM)-targeted therapeutics.PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells.Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells.Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors.Cell death-based treatment of neuroblastoma.Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review.Development and validation of a micellar liquid chromatographic method to determine three antitumorals in plasma.Structural pliability adjacent to the kinase domain highlights contribution of FAK1 IDRs to cytoskeletal remodeling.Replica to K. Takeda et al. Commentary to Pastore et al. (2014): epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors.Radiobrominated benzimidazole-quinoline derivatives as Platelet-derived growth factor receptor beta (PDGFRβ) imaging probes.Imatinib Inhibits GH Secretion From SomatotropinomasResistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies
P2860
Q21559453-09DE6507-F69B-429D-AE2B-6ABADFBA0ED3Q26739760-5A973638-5CFA-4EC0-A511-7DC60FB6C6F3Q26746028-A8B614D4-E071-4AAC-AD64-E6DB3F887034Q26775134-9C8165AE-9563-42F4-9929-DD0EAD46B064Q28289188-F9B0DFC9-943F-4158-AA75-DC81B1D89E04Q28545130-E0FA7DC9-B589-4246-83A0-9336341C383DQ28546317-01589517-A102-4CDE-AD3B-A144122C6EC1Q33776835-54BB6944-FA78-4248-AC1D-71378D2D35B4Q35039202-9C1D4D2B-BB7B-42C9-830B-C01FFBC22297Q35210664-BCCB3AAC-91A9-4E3F-9F27-0F5B466812D4Q35781121-713F9E90-2A06-43C4-AE57-65347A5F12B0Q36182795-A780A8E9-8D76-4983-948B-179748AC9C1EQ36244298-DE080DC3-9973-44FA-8782-FE352C2A2FA7Q36269224-C6AFDF1D-2B36-43D6-8140-86705A4DF8F9Q36280842-96C222B7-BF14-4DF8-9017-F690E2C59E14Q36857218-ECDC135E-8F4B-4C8A-A712-280A3AB7EDD9Q36947861-44EAA06B-4A1E-4332-BF01-0F3E2FEF4639Q36962501-4951B20E-4125-43AC-B299-E36B5D895536Q37723370-FAA29892-B73C-45AB-B3F0-BA7284A9A23DQ38095848-FD016094-D8A5-45AE-9185-AF5B97B6F5FFQ38167808-F599B554-E3D5-4908-BEF2-8F6C76F6A467Q38241160-EEA38141-573F-4CE4-90CC-F2F066E3B965Q38481540-B1687D0B-9642-402F-A2CE-7253824D0027Q38757723-7E8A7354-6F9F-4C97-AE59-59F505585C53Q38814898-843359F1-F201-4EB2-B4BA-034B33343835Q38906990-C5E69EBA-CA9E-4865-B5E3-CD671FEDBEC7Q38936710-1E4FCCF2-FAF0-416C-84ED-77B31B9298BEQ39008859-8B42E3A3-EB89-4864-8EEB-E02D3B214F3BQ39267549-BDA0432D-631D-4721-BC42-3BEAD29DEB6CQ41628138-FB786791-53E3-4A0C-99D0-21E5396975C1Q47124737-47033A22-AE66-46D3-811D-F1BED98EC606Q47401024-53119064-43C8-4164-A9E1-2657B3F11905Q47839039-886C8F67-FEAB-4931-B49D-DD76ADBA25D5Q49188770-20ABA625-517D-4C9B-AE53-77DF32EC17ABQ50638576-58EFB750-DE6E-4C70-8FD0-7669448ED0E2Q51414693-6EFD29E3-849C-499D-BB30-861D3D4202BAQ54311709-CC69208A-3947-405A-99E8-72BC5D5A65F7Q55655153-A995EB49-0927-4089-94D8-4CC33969B185Q58633992-F49852CC-EAA2-45FD-ADD2-D3D732D93401Q58739975-29805363-7D0A-4258-B8D2-17BDAC0EBDC4
P2860
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
@ast
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
@en
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
@nl
type
label
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
@ast
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
@en
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
@nl
prefLabel
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
@ast
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
@en
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
@nl
P2093
P2860
P356
P1476
Tyrosine kinase inhibitors: Multi-targeted or single-targeted?
@en
P2093
Elisa Giovannetti
Fleur Broekman
Godefridus J Peters
P2860
P356
10.5306/WJCO.V2.I2.80
P577
2011-02-01T00:00:00Z